Endothelial dysfunction is prevented by dapagliflozin A (SGLT2) inhibitors via SIRT1 activation, and it is ameliorated by restoring eNOS activity, NO bioavailability, and decreased ROS production (Zhou Y. et al., 2023). The gene discussed is SIRT1; the disease is endothelial dysfunction.